(Q37359616)

English

Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias

scientific article published on January 2009

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

1 reference

Europe PubMed Central

Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

author name string

Kathy M Makkar

1

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

Cynthia A Sanoski

2

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

Sarah A Spinler

3

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

language of work or name

0 references

publication date

1 January 2009

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

31-48

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

Electrical, contractile and structural remodeling during atrial fibrillation

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

Role of angiotensin receptor blockers in the prevention and treatment of arrhythmias

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

Development of a substrate of atrial fibrillation during chronic atrioventricular block in the goat.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

Angiotensin II modulates the delayed rectifier potassium current of guinea pig ventricular myocytes

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

Aldosterone-induced inflammation in the rat heart : role of oxidative stress

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

The impact of suppressing the renin-angiotensin system on atrial fibrillation

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

Pretreatment with ACE inhibitors improves acute outcome of electrical cardioversion in patients with persistent atrial fibrillation

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

The effects of statins and renin-angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.31

21 January 2018

Identifiers

10.1592/PHCO.29.1.31

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37359616&oldid=1702148826"